scispace - formally typeset
Z

Zichao Luo

Researcher at National University of Singapore

Publications -  47
Citations -  1776

Zichao Luo is an academic researcher from National University of Singapore. The author has contributed to research in topics: Adjuvant & Immune system. The author has an hindex of 17, co-authored 39 publications receiving 1198 citations. Previous affiliations of Zichao Luo include Chinese Academy of Sciences & Wenzhou Medical College.

Papers
More filters
Journal ArticleDOI

A Powerful CD8+ T-Cell Stimulating D-Tetra-Peptide Hydrogel as a Very Promising Vaccine Adjuvant.

TL;DR: A novel vaccine adjuvant based on a supramolecular hydrogel of a D-tetra-peptide is reported, expected to enable a wide range of sub-unit vaccines and help the production of antibodies.
Journal ArticleDOI

Enzyme-Catalyzed Formation of Supramolecular Hydrogels as Promising Vaccine Adjuvants

TL;DR: The d‐peptide hydrogel with OVA exhibits a slightly more efficient accumulation of OVA in the lymph nodes and seems preventing tumor growth more significantly than its l‐counterpart, suggesting big potential for the production of protein vaccines for immunotherapy against different diseases.
Journal ArticleDOI

Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses.

TL;DR: The in vitro study showed that reducible AP-SS nanogels not only facilitated antigen uptake by mouse bone marrow dendritic cells (BMDCs), but also promoted intracellular antigen degradation and cytosolic release.
Journal ArticleDOI

Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.

TL;DR: In vivo co-delivery of immunopotentiator (PIC) and immunosuppressive gene silencer (STAT3 siRNA) by nanovaccines are expected to be a promising strategy to improve the therapeutic efficacy of cancer vaccines by modulating TADCs and overcoming tumor immunosupression.
Journal ArticleDOI

In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications.

TL;DR: It could be concluded that the developed PEG hydrogels as an injectable hydrogel might be suitable for extended Avastin(®) release to treat the corneal neovascularization.